Merck
$MRK (+2,2%) has significantly scaled back the targets for its Pharmaceuticals division after two failed drug candidates.

Despite a decline in profits in 2023, the company is aiming to benefit from the current boom phase in the AI and semiconductor semiconductor industry with annual sales growth in the electronics division of five to nine percent.

In the pharmaceutical business however, only a slight increase in turnover is expected. The forecasts for the laboratory business have also been revised downwards due to disappointed expectations in China.

CEO Belen Garijo confirmed the optimistic forecast for the current year, supported by successes in the area of cancer drugs. -Handelsblatt

Photo: Merck KGaA